Resources
22 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/3/2021 (updated 4/10/2024)
During this session, TELs reviewed the Cohort specific sustainability template and answer questions from grantees ahead of the HRSA due dates in the fall.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 5/25/2021 (updated 4/10/2024)
This webinar will introduce grantees to the RCORP evaluation portal and review how various data and charts can inform sustainability strategies.
Learning objectives:
Learn how to access and utilize the RCORP evaluation portal
Understand what data in the portal can inform sustainability strategies
Posted 5/17/2021 (updated 4/10/2024)
This webinar will present the OUD Cascade of Care, explain how to create one for your program and use it to evaluate and sustain your MOUD continuum of care.
Learning Objectives:
Understand the cascade of care for opioid use disorder (OUD)
Define metrics for your OUD cascade of care
Use the cascade of care to take action that improves sustainability
Target Audience: Implementation I, Implementation II, MAT Expansion, but all cohorts are welcome
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 11/11/2021 (updated 4/3/2024)
This session provided participants with realistic and achievable steps to help consortiums leverage their RCORP-Planning efforts to achieve long-lasting sustainable impact. Participants heard from two RCORP-Planning III sites that are successfully navigating and securing sustainability for their communities using different approaches.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)